Uveal Melanoma and Brachytheraphy: Long-term Outcomes.

Long-term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy

This study investigated the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival in patients affected by uveal melanoma and undergoing Ru-106 plaque brachytherapy between February 2011 and March 2020

Inclusion Criteria:

• age older than 40 years
• diagnosis of uveal melanoma

Exclusion Criteria:

• age older than 80 years
• No diagnosis of uveal melanoma